2005
Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients
Rostom A, Goldkind L, Laine L. Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients. Clinical Gastroenterology And Hepatology 2005, 3: 489-498. PMID: 15880319, DOI: 10.1016/s1542-3565(04)00777-3.Peer-Reviewed Original ResearchConceptsLiver-related deathLiver-related hospitalizationsSerious adverse eventsAnti-inflammatory drugsAminotransferase elevationAdverse eventsSide effectsNonsteroidal anti-inflammatory drugsTrials of diclofenacHepatic side effectsProportion of patientsClinical side effectsRandomized Controlled TrialsBibliographic databases MEDLINEHigh rateArthritis patientsControlled TrialsRheumatoid arthritisHepatic toxicityInclusion criteriaDatabases MEDLINENSAIDsDrug AdministrationSystematic reviewToxicity outcomes
2004
Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy
Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy. Alimentary Pharmacology & Therapeutics 2004, 19: 197-208. PMID: 14723611, DOI: 10.1111/j.0269-2813.2004.01834.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitorsCost of NSAIDsPump inhibitorsGastrointestinal eventsChronic anti-inflammatory therapyRAND/UCLA Appropriateness MethodNon-steroidal anti-inflammatory drugsAnti-inflammatory therapyAnti-inflammatory drugsDrug treatment strategiesCommunity-based settingsCardiovascular riskProphylactic useAppropriateness MethodTreatment strategiesLower riskNSAIDsPatientsClinical scenariosAspirinAppropriate useInhibitorsRiskCare entitiesLiterature review
2003
Proton pump inhibitor use in patients with indications for low-dose aspirin who start COX-2 selective inhibitors or nonselective NSAIDs
Ofman J, Knight K, Badamgarav E, Henning J, Wallace K, Wong J, Dylan M, Laine L. Proton pump inhibitor use in patients with indications for low-dose aspirin who start COX-2 selective inhibitors or nonselective NSAIDs. Gastroenterology 2003, 124: a107. DOI: 10.1016/s0016-5085(03)80529-2.Peer-Reviewed Original ResearchGI healthcare resource use in 6009 patients switching from chronic NSAID to COX-2 specific inhibitor therapy and the effect of prior PPI use
Laine L, Von Allmen H, Henderson S. GI healthcare resource use in 6009 patients switching from chronic NSAID to COX-2 specific inhibitor therapy and the effect of prior PPI use. Gastroenterology 2003, 124: a108. DOI: 10.1016/s0016-5085(03)80531-0.Peer-Reviewed Original ResearchDo NSAIDs induce esophagitis? The effect of non-specific NSAIDs and COX-2 specific inhibitors±low-dose aspirin in prospective, randomized, double-blind, placebo-controlled endoscopic trials
Laine L, Goldstein J, Fort J. Do NSAIDs induce esophagitis? The effect of non-specific NSAIDs and COX-2 specific inhibitors±low-dose aspirin in prospective, randomized, double-blind, placebo-controlled endoscopic trials. Gastroenterology 2003, 124: a511. DOI: 10.1016/s0016-5085(03)82586-6.Peer-Reviewed Original Research
1999
Review article: nonsteroidal anti‐inflammatory drug‐associated gastrointestinal complications—guidelines for prevention and treatment
Schoenfeld, Kimmey, Scheiman, Bjorkman, Laine. Review article: nonsteroidal anti‐inflammatory drug‐associated gastrointestinal complications—guidelines for prevention and treatment. Alimentary Pharmacology & Therapeutics 1999, 13: 1273-1285. PMID: 10540041, DOI: 10.1046/j.1365-2036.1999.00617.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGastrointestinal complicationsPylori infectionSerious gastrointestinal complicationsH. pylori infectionHelicobacter pylori infectionProton pump inhibitorsLowest possible dosagePotential of treatmentNSAID therapyNSAID useAnalgesic therapyCorticosteroid useGastrointestinal bleedingUlcer diseaseAntisecretory agentsPump inhibitorsChronic ingestionPain relieversNSAIDsComplicationsPatientsExact associationPossible dosageRoutine testingPast history
1993
HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA
Laine L. HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA. Gastroenterology Clinics Of North America 1993, 22: 117-125. PMID: 8449561, DOI: 10.1016/s0889-8553(21)00267-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsH. pylori prevalenceGastric ulcerHistologic gastritisH. pyloriGastric injuryPylori prevalenceDuodenal ulcerGastric mucosaNoxious agentsInflammatory cell infiltrateH. pylori infectionNSAID usersCell infiltratePylori infectionDuodenal contentsNSAIDsUlcersGross injuryGastritisPatientsHelicobacter pyloriPyloriInjuryMucosaPrevalence